drugset
drugset / Trial / NCT06369675

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675 ↗

Phase 1 Completed 45 enrolled Moberg Pharma AB
NaSingle-groupOpen-labelOther

Summary

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject comparison study

Timeline

Start
2017-10-19
Primary completion
2017-11-14
Completion
2017-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbinafine Small molecule — Topical

Indications

No indication recorded.